Back to Results

A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients with Advanced Solid Tumors

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

Part B: Pathologically confirmed (histology or cytology) of the following cancer types: a. Cohort 1: taxane naive advanced/metastatic gastric cancer, lung cancer, head and neck cancer, or ovarian cancer b. Cohort 2: taxane naive advanced/metastatic breast cancer c. Cohort 3: taxane naive advanced/metastatic prostate cancer d. Cohort 4: advanced/metastatic breast or ovarian cancer patients who have either progressed on a taxane or have developed progressive disease within 6 months of receiving a taxane

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Alexis Leal,  MD

Alexis Leal, MD

Study ID

Protocol Number: 21-3561

More information available at ClinicalTrials.gov: NCT04931823

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers